Business
Satellos Expands Leadership Team with New CFO Appointment
Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy for public biotech companies listed on Nasdaq
About this update from Promis Neurosciences Inc.
[{"type":"text","content":"\nElizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy for public biotech companies listed on Nasdaq and TSX.\nCurrent CFO, Warren Whitehead, CPA, CMA, transitions to Head of Corporate Strategy to focus on strengthening and expanding collaborations and partnerships.\nSatellos is advancing a potentially first-in-class small molecule drug candidate to clinical trials for Duchenne muscular dystrophy.\n\nToronto, Ontario--(Newsfile Corp. - September 5, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (\"Satellos\" or the \"Company\"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the appointment of Elizabeth (Liz) Williams, CPA, CA, as Chief Financial Officer (CFO). Warren Whitehead, CPA, CMA, who has served as CFO for Satellos for two years, will now become Head of Corporate Strategy. These management updates were effective as of September 1, 2023.\nFrank Gleeson, Co-founder and CEO of Satellos, said, \"Warren's depth of experience has guided Satellos through our key financial milestones, from going public in 2021 to our recent CA$55 million financing with leading healthcare institutional investors. I'm excited to welcome Liz, who bolsters our leadership team with extensive experience in financial transactions and capital markets, including uplisting to Nasdaq. I look forward to working closely with them both as we advance into the clinic a completely novel small molecule approach with the potential for a disease-modifying treatment for Duchenne muscular dystrophy.\"\n\"With the company's recent financing, Satellos has the support and confidence of a high-quality group of healthcare-focused investors,\" said Ms. Williams. \"Satellos is making significant progress in advancing a small molecule drug candidate for Duchenne muscular dystrophy that has the potential to be a meaningful therapeutic approach complementary to genetic medicines. I look forward to supporting the advancement of this leading program to the clinic.\"\nElizabeth Williams, CPA, CA\nMs. Williams has nearly 20 years of experience in biotech, working with publicly listed entities in both Canada and the United States. Prior to joining Satellos, Ms. Williams was CFO of Medicenna (NASDAQ: MDNA), ...